| Accession |
PRJCA022876 |
| Title |
Comparison of SCT510 combined with paclitaxel and carboplatin in first-line treatment of non-small cell non-small cell lung cancer with the combination of anweiting, paclitaxel, and carboplatin |
| Relevance |
Medical |
| Data types |
Nucleic acid biomarkers
|
| Organisms |
Homo sapiens
|
| Description |
Evaluation of recombinant humanized anti VEGF monoclonal antibody injection (SCT510) in combination with paclitaxel and carboplatin compared to bevacizumab amphotericin The efficacy, safety, immunogenicity, and SCT510/Avastin in the first-line treatment of locally advanced, metastatic, or recurrent non-small cell lung cancer with the combination of paclitaxel and carboplatin Pharmacokinetic characteristics of repeated administration. |
| Sample scope |
Multiisolate |
| Release date |
2024-02-29 |
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| Other
|
|
N/A
|
|
|
|
| Submitter |
Wenwen
Ren (wenwen_ren@sinocelltech.com)
|
| Organization |
Sinocelltech Ltd |
| Submission date |
2024-01-15 |
